Dinutuximab

Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer[1][2][3].

Product Specifications

CAS Number

[1363687-32-4]

Product Name Alternative

APN-311; Ch14.18; MAb-14.18

UNSPSC

12352203

Target

Apoptosis; mTOR; PERK

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/dinutuximab.html

Purity

99.0

Solubility

10 mM in DMSO|H2O

Smiles

[Dinutuximab]

Molecular Weight

(145.012 kDa)

References & Citations

[1]Ploessl C, et al. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma. Ann Pharmacother. 2016 May;50 (5) :416-22.|[2]Barry WE, et al. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma. Clin Cancer Res. 2019 Jan 1;25 (1) :325-333.|[3]Ly S, et al. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like cells. J Immunother Cancer. 2021 Mar;9 (3) :e001197.